Neşe ÇÖLÇİMEN
Neuro-Cell Molecular Research - 2026;3(1):27-30
Psoriasis is a chronic, recurrent, autoimmune, inflammatory skin disease. While psoriasis was considered limited to the skin in the past, it is now recognized as a chronic systemic inflammatory disease accompanied by many comorbidities. The main comorbidities of the disease are non-alcoholic fatty liver disease (NAFLD), mood disorders including depression, cardiometabolic diseases including myocardial infarction, hypertension, type 2 diabetes mellitus, hyperuricemia, dyslipidemia, obesity, metabolic syndrome, and psoriatic arthritis. NAFLD is estimated to have a prevalence of 25% in the general population and is a leading cause of cirrhosis and liver transplantation. Currently, NAFLD has become an escalating epidemic, driven by the rising incidence of obesity, metabolic syndrome, and insulin resistance, as well as the systemic effects of psoriasis itself. This review aims to highlight the adverse effects of psoriasis, a skin disease requiring long-term medication, on the liver, and to emphasize these effects when planning treatment regimens.
